RetinalGenix Technologies Inc. Overview
Pro stress-test →RetinalGenix Technologies Inc. is an innovative ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes by leveraging proprietary High-Resolution Retinal Imaging and DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ technologies designed to detect initial physiological changes that could indicate future ocular and systemic diseases including neurodegenerative, cardiovascular, vascular, metabolic systems, diabetic conditions, Alzheimer's disease and Parkinson's disease. The company is also developing therapeutic drugs for dry age-related macular degeneration (dry AMD) and Alzheimer's disease/dementia.
Strategic Profile
Pro stress-test →By integrating genetic screening, advanced imaging, and therapeutic development, RetinalGenix is positioned to become a leader in precision medicine. In February 2025, the company achieved an important milestone by successfully starting imaging patients with its first prototype device using both near-infrared and green modes. In October 2025, RetinalGenix announced a strategic partnership with RGEN Inc., a leader in genetic research and innovation, to deliver advancements in the early detection and risk prediction of neurodegenerative, systemic, and retinal diseases.
Competitive Landscape
Pro stress-test →RetinalGenix operates in the emerging precision medicine diagnostics space for ocular and systemic disease detection. Direct competitors in retinal imaging and early disease detection include Heidelberg Engineering (ophthalmology diagnostic devices), Zeiss (advanced optical imaging systems), and Optos (wide-field retinal imaging). In the broader genetic/pharmacogenetic mapping space, competitors include Quest Diagnostics, LabCorp, and specialized genomics firms. The combination of imaging + genetic mapping is less crowded, positioning RetinalGenix as a differentiated player if clinical validation succeeds.
Industry Context
RetinalGenix Technologies Inc. operates in Precision medicine diagnostics for retinal and systemic disease detection.
Key facts
Founded: 2017 · Headquarters: Apollo Beach, Florida, USA · Employees: Not disclosed · Revenue: Not reported · Market cap: $65.6M (as of July 21, 2025)